Remember that "Vectura has also selected Carclo as the development partner for its innovative Gyrohaler(R) device, adding to the family of inhalers we are manufacturing for Vectura"...
Today Vectura have announced a huge collaboration agreement:
They say:
"Combination therapy is the biggest and fastest growing sector of the respiratory market with worldwide annual sales currently exceeding $8 billion and US annual sales estimated to exceed $4 billion.
Vectura's GyroHaler(R) is a multi-dose DPI developed with the aim of providing a number of advantages over other inhaler devices. These include better
convenience for patients, more consistent, precise dosing and excellent moisture protection, a key distinguishing factor in inhaled drugs which are in a fine powder form."
Looks like another near-term blue-sky winner for CAR.
Avis Budget Grp stock quotes
Avis Budget Grp stock charts
Follow this thread
